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Abstract
GENETIC MANIPULATION OF THE RELAPSING FEVER SPIROCHETE BORRELIA
HERMSII PERMITS NOVEL INVESTIGATION INTO THE ROLE OF FACTOR H BINDING
IN BORRELIAL VIRULENCE
By Lindy M. Fine, B.A.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.
Virginia Commonwealth University, 2011
Director: Richard T. Marconi, Ph.D.
Professor, Department of Microbiology and Immunology

Borrelia hermsii, an etiologic agent of tick-borne relapsing fever, binds negative
complement regulator factor H (FH) via its FhbA protein. Direct demonstration of the role of
FhbA in the disease process has been hindered by the lack of genetic manipulation systems for
the relapsing fever Borrelia. Here, we demonstrate successful generation of a B. hermsii strain
YOR fhbA deletion mutant (Bh YORΔfhbA) that constitutively produces green fluorescent
protein (GFP). Genetic manipulation did not affect growth rate or plasmid composition. Bh
YORΔfhbA lost factor H-binding and C3b-inactivation capabilities, but retained resistance to
killing in human serum and infectivity in mice. Stable production of GFP was demonstrated in
vitro and in vivo. Collectively, these results suggest that B. hermsii employs an unidentified
mechanism of complement evasion that is FH-independent and sufficient for persistence within
the host. Additionally, this study represents a significant methodological advancement in the

molecular characterization of relapsing fever spirochetes.

Introduction

Borrelia and human health
Pathogenic Borrelia species include the causative agents of Lyme disease and relapsing
fever (14, 157), earning the genus an important place in the history of public health. Lyme
disease (LD) is a significant infectious disease of modern times, and has undergone marked
range expansion since it was first recognized in the United States several decades ago (71, 158).
Currently, Lyme disease, caused by B. burgdorferi in North America and B. burgdorferi, B.
garinii, and B. afzelii in Europe (7, 97), is the most common tick-borne disease in the Northern
Hemisphere (32, 156, 174).
Relapsing fever (RF) is an ancient disease that was documented during the time of
Hippocrates. However, it was not until 1873 that a spirochetal etiologic agent of the louse-borne
form of relapsing fever was identified. In the centuries surrounding this discovery, epidemics of
louse-borne relapsing fever (LBRF) devastated populations worldwide (24). Most widespread
outbreaks of the 20th century were associated with wartime (the World Wars in particular) and
ensuing conditions of poverty and poor sanitation. In the first half of the century, there were
millions of cases of relapsing fever in Africa and the Balkans, and the disease caused more than
5 million deaths in Russia alone (24, 42, 126). Today, epidemic LBRF remains largely confined
to northeastern Africa. Ethiopia is a focal point of infection and reports approximately 10,000
cases per year (24).
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Not attributed to the spirochete until 1904 (133), tick-borne relapsing fever (TBRF) has
had a more understated, but equally persistent, role in human history as an endemic disease
regionally affecting most of the world aside from Australia, New Zealand, and Oceania (55).
Today, TBRF remains a significant human health concern. Its impact is most dramatically felt in
parts of Africa (Tanzania, Ethiopia, Senegal, Mauritania, and Mali) (41, 45, 82) where it is the
most common cause of fever, surpassing even malaria, in certain regions (168). In the heavily
impacted Tanzanian village of Mvumi, TBRF sickens nearly 40% of children less than one year
of age and is the seventh most frequent cause of childhood mortality (164). Complicating the
present situation, TBRF is not a reportable disease in many African countries; thus, the current
epidemiology of this disease is poorly understood. A 2004 study underscored this point by
revealing that 8.8% of ―fever‖ patients in Togo in fact suffered from TBRF, a disease unknown
in that country previously (116). TBRF is also endemic to regions of North America, Mexico,
Central and South America, the Mediterranean, and Central Asia (48). In North America, TBRF
occurs sporadically west of the Mississippi River in the United States, as well as in southern
British Columbia, Canada (22, 47, 49, 62, 144, 148, 155, 167).

Etiology and transmission of relapsing fever
Relapsing fever is caused by at least 15 different Borrelia species (127, 130) that are
transmitted to humans by arthropod vectors. LBRF is distinguished from other forms of the
disease by several unique etiological features. It is caused exclusively by the spirochete B.
recurrentis, and is transmitted by the human body louse, Pediculus humanus humanus (126).
Infection with LBRF does not occur through bites of feeding arthropods, but rather through
autoinoculation of abraded skin with infected louse hemolymph and possibly feces (75). Spread
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of this disease is highly dependent upon human-louse association for several reasons. First,
LBRF is not a zoonosis; rather, humans act as the sole mammalian host (14). Secondly, because
transovarial transmission of spirochetes does not occur in lice, the naive louse may become
infected only through immediate interaction with a spirochetemic human (55).
In contrast, TBRF is caused by a number of different Borrelial species, including the Old
World TBRF spirochetes B. duttonii, B. crocidurae, and B. persica, and the North American
spirochetes B. hermsii and B. turicatae (54, 67). All are transmitted to humans through bites of
infected argasid Ornithodoros ticks. Because TBRF spirochetes are present in tick salivary
glands, direct transmission to the host occurs even during the alacritous (20 min-1 hr)
bloodmeals typical of soft-bodied ticks (143). The bacterium-vector relationship for TBRF
spirochetes is thought to be highly specific—generally each Borrelia species associates with a
single vector, and vice versa (e.g., B. crocidurae is transmitted only by O. sonrai, B. turicatae
only by O. turicata, etc.) (169). Many TBRF vectors are long-lived and capable of transmitting
infection transovarially, making them efficient Borrelial reservoirs and lessening the ecological
reliance of many TBRF spirochetes on vertebrate hosts (55).
TBRF is generally an enzootic disease of which humans are accidental hosts. The
exception to this is B. duttonii, transmitted by O. moubata, for which no natural hosts other than
humans have been identified (55). Other animals important in the TBRF enzootic cycle include
small mammals (particularly rodents), and possibly reptiles, birds, and bats (52, 58, 135, 145,
147, 162). Cases of relapsing fever in domestic dogs and horses have also been documented
(129, 146, 171).
In North America, TBRF is most often caused by B. hermsii. The tick vector, O. hermsi,
is primarily encountered in the coniferous, high-elevation forests of the western United States.
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Pine squirrels (Tamiasciurus spp.) and chipmunks (Tamias spp.) are important natural hosts for
B. hermsii, and the majority of human cases occur in individuals vacationing in rustic cabins that
provide a natural interface with both rodent and tick (25, 46, 148).

Clinical disease
Relapsing fever is characterized by recurring episodes of high fever that coincide with the
occurrence of large numbers of spirochetes in the blood (54). Manifestations of TBRF and
LBRF in humans are very similar, although the latter tends to cause more severe disease. After
an incubation period of 2-18 days, illness begins abruptly with nondescript, flu-like symptoms
such as fever, headache, myalgia, and arthralgia. Fever (often ≥ 104°F) may be accompanied by
vomiting, dizziness, or delirium. Tachycardia, hepatomegaly (with or without jaundice), and
splenomegaly are commonly observed (154). LBRF is sometimes associated with hemorrhagic
phenomena such as the development of petechiae and/or epistaxis (25-50% of cases). A variety
of respiratory, cardiac, neurological, and ocular complications occur less commonly (126).
Without treatment, symptoms persist for 2-7 days until the individual generates an antibody
response sufficient to cause mass clearance of circulating organisms. This results in liberation of
bacterial components in the bloodstream and subsequent host release of pro-inflammatory
cytokines, causing a crisis of rigors, hypotension, and diaphoresis. Cardiovascular collapse
occasionally results (46), and the majority of deaths occur during this phase of infection. The
crisis is followed by temporary symptom resolution and spirochetemic relapses of decreasing
severity.
Diagnosis is typically made by microscopic observations of spirochetes in the patient’s
blood (44). However, this method requires that blood be examined during febrile peaks, and even
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then spirochetes will be present in only about 70% of samples (154). A more sensitive method
involves recultivation of spirochetes from patients’ blood either in liquid culture or through
inoculation of susceptible laboratory animals (46, 154). Serological or PCR-based methods are
occasionally used in research settings or in isolated clinical cases.
Treatment of relapsing fever consists of antibiotics (doxycycline, erythromycin, or
chloramphenical) administered over the course of seven days (44). Antibiotic administration
often precipitates a Jarisch-Herxheimer reaction (J-HR), which is akin to the crisis phase of
natural infection and similar to the classic endotoxin reaction. Borrelia lack LPS (see next
section), but actions of the antigenic variable major proteins (Vsp/Vlp) have been implicated in
this inflammatory process (149, 170). Within the host, J-HR is associated with increased plasma
levels of IL-6, IL-8, and TNFα (114), and pre-treating patients with anti-TNFα antibodies has
been shown to attenuate the reaction’s severity (53).
Without treatment, case mortality rates range from 4-10% for TBRF and 10-40% for
LBRF; antibiotic therapy decreases these numbers to <5% (126). Much higher rates of death (up
to 70% (24)) were documented during past epidemics, likely a result of malnourishment and
generalized poor health among the affected populations.

Cell structure and genetics
The Borrelia are variably sized spirochetes, ranging from 8-30 µm in length and from
0.2-0.5 µm in width (14). They have a diderm membrane ultrastructure (85) but, unlike
traditional Gram-negative organisms, lack lipopolysaccharide (LPS) (163). Between the outer
membrane sheath and the protoplasmic cylinder, Borrelia have a variable number (7-30) of
periplasmic flagella organized in flat, ribbon-like formations (14, 34). Interactions between the
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flagella and the cell cylinder confer upon Borrelial spirochetes a distinctive flat-wave
morphology and translational motion (66).
The Borrelia have an extremely unusual, fragmented genomic structure consisting of a
linear chromosome and multiple linear and circular plasmids (10, 14, 16, 56). This unique
genomic composition, dominated by extrachromosomal elements and covalently-closed linear
DNA molecules (13, 33), appears to be ubiquitous among both Lyme and RF spirochetes (30, 83,
92). The linear chromosome of B. burgdorferi type strain B31 has a G+C content of 28.6% and
bears most housekeeping genes amidst the compactly arranged coding sequences that
collectively occupy 93% of the chromosome (60). Additional sequencing data have suggested
that this organization is generally conserved among Borrelia species. In contrast, Borrelial
plasmid compositions can vary markedly among even isolates of the same species. Events
associated with this variability include plasmid loss and intragenomic recombination (98, 99,
142). The latter may occur through homologous or non-homologous recombination events that
result in gene duplications and truncations, as evidenced by the numerous paralogous genes and
pseudogenes that have been identified on some circular and most linear plasmids (29, 31, 60).
Also unusual for bacterial extrachromosomal elements, Borrelial plasmids (including the
prophage cp32 family) encode a variety of primarily lipoprotein factors essential for infectivity
and transmission (160). Cp26 carries diverse genes including resT, guaA, guaB, and ospC (33,
100) and is uniquely critical to spirochetal survival and in vitro growth.
Examinations of chromosomal sequences have also revealed that Borrelia retain only
basic metabolic capabilities, lacking genes for de novo synthesis of amino acids, fatty acids, and
nucleotides (60). As a result of their minimalist genomes, Borrelia spirochetes are fastidious and
entirely dependent upon vertebrate or invertebrate hosts (the genus contains no known free-living
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species). Implications of this in the laboratory context include the requirement for highly
complex media during cultivation (14).

Pathobiology and immune evasion
RF spirochetes are predominantly blood-borne pathogens and reach densities in the host
bloodstream as high as 108 spirochetes per milliliter (54, 154). Within the blood, interactions
with cellular components may contribute to spirochetal pathogenicity. B. crocidurae, B. duttonii,
and B. hispanica have been demonstrated to aggregate erythrocytes into spirocentric rosettes via
interaction with erythrocyte neolacto- glycans (70). The role of this process during infection is
unknown, but both immune-evasive (26) and disseminative (152) functions have been proposed.
Additionally, thrombocytopenia is the most common clinical finding of TBRF (47), and the
interaction of Borrelia spirochetes with human and rodent platelets has been well-documented
(2, 4, 35, 64). In relapsing fever, formation of spirochete-platelet complexes appears to directly
induce thrombocytopenia through elevated platelet clearance (4). The precise mechanism of this
interaction is unknown, as platelet integrin αIIb3 mediates Borrelial attachment in vitro (2, 35)
but has been demonstrated to be nonessential during infection (4).
Complications associated with relapsing fever, including neuroborreliosis, arthritis, and
carditis, reflect the pathogen’s ability to disseminate extravascularly (27, 65, 94, 117, 151).
Studies have suggested that, like the closely-related Lyme disease Borrelia, relapsing fever
spirochetes display tropism for brain and collagenous tissues (28), and that specific tissue
tropism may be serotype-dependent (94, 109, 150). In addition to causing direct tissue damage,
low-level extravascular persistence may contribute to disease reactivation following immune
system compromise (90) or co-infection (e.g., with malaria) (96).
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Dissemination from circulating blood involves passage across tissue barriers such as the
extracellular matrix and the vascular basement membrane. Recruitment of host-derived
plasminogen (zymogen of the serine protease plasmin) has been demonstrated in both Lyme and
relapsing fever Borrelia (63, 69, 81, 88, 134, 141). In Borrelia burgdorferi, plasminogen binding
enhances penetration of endothelial monolayers in vitro (38, 68), while, for RF spirochetes,
plasminogen has been shown to play an important role in heart, kidney, and brain invasion (65,
117).
Host clearance of RF spirochetes is achieved through an IgM-mediated, T cellindependent immune response in which the B1b B cell subclass appears to play a central role (3,
11, 40, 115). This adaptive immune response, although efficacious and rapid, is serotypespecific. Therefore, to evade antibody-mediated immunity, RF Borrelia employ a prototypical
antigenic variation system involving variable major lipoproteins Vsp and Vlp (9, 15, 161). This
system is founded on multiple silent (―archived‖) versions of vlp and vsp genes scattered
throughout genomic linear plasmids; 59 vlp/vsp alleles have been identified (43). A single
expression locus for these genes resides near the telomere of a 28-kb linear plasmid, into which
any one of the silent genes may be copied, in its entirety, through non-reciprocal recombination.
Specific upstream and downstream homology sequences appear to mediate this recombination
and to dictate an observed hierarchy of switch rates between variants (12). Serotypic variants
spontaneously arise, both in vivo and in culture, at a frequency of 10-4-10-3 events per cell per
generation (119).
Innate immunity appears to play a role in controlling Borrelial infections (20), although
the mechanisms remain poorly defined. The ability of RF Borrelia to functionally evade innate
immunity, however, is clearly demonstrated by the massive and sustained bacteremia caused by
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these organisms. Many pathogens exploit host complement regulatory processes as a means of
innate immune evasion, usually through production and/or recruitment of factors that negatively
regulate the complement cascade (6, 18, 19, 61, 74, 112, 113, 118, 123, 125, 128, 140, 165).
These mechanisms have been documented in many pathogenic spirochetes including Leptospira
species (8, 159), Treponemes (103, 104), and Lyme and relapsing fever Borrelia.

Complement and factor H
The complement system is comprised of more than 30 soluble and cell-surface proteins
that act in concert to eliminate pathogens by opsonization and lytic events. Many complement
proteins exist in the body as zymogens that are sequentially activated through a cascade of
cleavage reactions. Such activation can occur by way of three pathways (classical, lectin, and
alternative) that differ in their mechanisms of initiation but ultimately converge in the terminal
stages of activity (72, 138).
Both the classical and the lectin pathway are activated by distinct recognition
mechanisms including, for the former, antigen-complexed antibodies, and, for the latter, specific
cell-surface arrangements of mannose residues. In contrast, low-level activation of the alternative
pathway occurs independently and spontaneously in the plasma. This process results in local
pools of activated C3b that bind carbohydrates and proteins on nearby cell surfaces via exposed,
highly reactive thioester bonds (120). If binding fails to occur, C3b is quickly inactivated by
hydrolysis (172). Upon binding to an activating surface (e.g., a pathogen), C3b is bound by
zymogen factor B, which is itself cleaved and activated by factor D. The large Bb fragment
remains in association with C3b, forming the alternative pathway C3 convertase, C3bBb. Both
the classical and the lectin pathway lead to the generation of functional equivalents of this
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enzyme; therefore, the pathways converge at this stage. The C3 convertase generates high local
levels of active C3b fragments, which act independently as opsonins or complex with the C3
convertase to form the C5 convertase (for the alternative pathway, C3b2Bb) (173). This enzyme
cleaves and activates C5, generating C5a, a potent anaphylatoxin, and C5b, the earliest
membrane attack complex (MAC) component. During MAC formation, the terminal complement
components assemble as follows: C5b binds C6 and C7 which, in complex, undergo
conformational changes and insert into the pathogen cell membrane via a hydrophobic region on
C7. This allows C8 to bind, insert into the membrane, and induce the final component, C9, to
bind and polymerize. The resulting pore-like structure is cytolytic and promotes elimination of
target cells (138).
The complement cascade is tightly regulated by a variety of cell-surface and fluid-phase
proteins to prevent uncontrolled or inappropriate activation within the host (175). Factor H (FH)
is the major fluid-phase regulator of the alternative complement pathway. A plasma protein of
155 kDa, human FH is composed of individually folding domains known as short consensus
repeats (SCR) which are joined by short, flexible linking sequences (139). Domain conformation
is maintained by disulfide bonds that form in a 1-3 and 2-4 manner between four conserved
cysteine residues harbored within each SCR. A critical element of alternative pathway regulation
involves specific discrimination between self-cells and pathogens targeted for destruction. This
specificity is largely conferred by FH, which contains multiple heparin-binding sites that interact
with polyanionic regions present on human cells and tissues (but generally absent from
microbial surfaces), such as glycosaminoglycans (GAGs) and sialic acid residues. The most
well-characterized heparin-binding sites are contained within SCRs 7 and 20, and an additional
site is present within SCRs 9-15 (57, 139, 140, 176). Interactions with such polyanionic surfaces
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enhance the binding affinity of FH for C3b (111) and allow FH to inhibit cascade progression by
several mechanisms, including cofactor activity in the factor-I mediated cleavage of C3 and
destabilization of the C3 convertase (172).

Borrelial factor H binding and FhbA
As discussed, many pathogenic spirochetes exploit the protective capacity of exogenous
FH by recruiting it to surface-expressed proteins during host infection. This process has been
most extensively examined in the LD species B. burgdorferi, which produces five factor Hbinding proteins (FHBPs) including CspA (BBA68/CRASP-1); CspZ (BBH06/CRASP-2); and
OspE family proteins BBN38, BBL39, and BBP38 (CRASP3-5, respectively) (1, 23, 73, 80, 102,
107). Other Borrelial species that produce FHBPs include LD spirochete B. afzelli and RF
spirochetes B. recurrentis, B. parkeri, and B. hermsii (69, 78, 108, 141). Among the RF species,
the FH-binding mechanism of B. hermsii and its single FHBP, factor H-binding protein A
(FhbA), are most well characterized.
FhbA is a ~20-kDa outer surface lipoprotein that is encoded by a single copy gene borne
on the 200-kb linear plasmid lp200 (78). Production of FhbA is widespread among low-passage
B. hermsii isolates; however, several high-passage strains (RENHP, FROHP, CONHP) have been
found to lack the fhbA gene and lp200, and rather to harbor a 170-kb linear plasmid. This change
is consistent with the linear plasmid rearrangement frequently observed in Borrelia, and also
suggestive that fhbA may be of prophage origin. Two phyletic fhbA groups (fhbA1, fhbA2) have
been identified (79) and correlate well with B. hermsii genomic group (GG) designations
previously established through sequence analyses of chromosomal loci (flab, glpQ, and gyrB)
(122). FhbA is expressed during infection and has been demonstrated to be highly immunogenic
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(39, 76, 78, 79). In addition to FH, FhbA binds other serum proteins including FHL-1 (a FH
splice variant with complement regulatory and adhesive functions) and plasminogen (77).
FH binding is essential to complement resistance in the spirochete Treponema denticola
(101). In the Borrelia, evidence supports the notion that FH-binding ability is linked to resistance
to complement-mediated killing in vitro and during infection (23, 76, 86, 108, 131). However,
direct demonstration of the role of FH binding in the Borrelial disease process, achieved
traditionally through gene inactivation, has not yet been possible.

Genetic manipulation of relapsing fever spirochetes
The first demonstration of genetic manipulation of a Borrelia species was in the Lyme
disease spirochete B. burgdorferi (136). Although applications of Borrelial molecular genetics
have broadened considerably, the same basic methods are still largely observed (132). While
standard techniques are employed to introduce DNA by electroporation, large amounts of DNA
are required to overcome the Borrelia’s notoriously low transformation efficiency (166). An
important and confounding factor in the genetic manipulation of B. burgdorferi is
transformation-associated loss of endogenous plasmids that encode proteins required for survival
in either tick or mammalian hosts (91, 124, 132).
To date, there is only a single report of site-directed allelic exchange in a RF Borrelia
species (17) and diverse tools for this purpose are lacking. Although chromosome sequences of
B. hermsii (GGI DAH isolate), B. turicatae, B. recurrentis, and B. duttonii (92) are now
available, assembled, annotated, and complete sequences for plasmid components of these
genomes have not yet been determined.
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Research objectives
Prior to clearance by serotype-specific, antibody-mediated adaptive immune processes,
RF spirochetes persist at extremely high levels in the host bloodstream (154). This high-level
bacteremia suggests facilitation by spirochetal mechanisms of innate immune evasion. One such
putative mechanism involves recruitment of host-derived factors that negatively regulate the
complement cascade. Binding of FH, the primary fluid-phase regulator of the alternative
complement pathway, has been demonstrated in a variety of pathogens including Borrelia
species (61, 74, 112, 113, 140). TBRF spirochete B. hermsii binds FH via its FhbA protein (78).
However, direct demonstration of the role of FhbA in the disease process has been precluded by
the lack of a reliable genetic manipulation system for RF Borrelia. In an effort to develop
molecular tools for this purpose while exploring the role of FH binding in Borrelial virulence,
this work addresses the following aims:

1. Expand the genetic tools available for studying the molecular pathogenesis of RF
spirochetes
Molecular characterization of TBRF spirochete B. hermsii has been hindered by
methodological challenges; this objective will involve refining existing techniques to
overcome these challenges. Site-specific allelic exchange mutagenesis and a unique
kanamycin resistance-green fluorescent protein construct will be utilized to achieve
genetic transformation of B. hermsii strain YOR. Resulting transformant clones will
be characterized both in vivo and in vitro.

2. Directly assess the role of FH binding in the virulence of TBRF Borrelia
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Using genetic transformation techniques, a B. hermsii strain YOR fhbA deletion
mutant will be generated. Analyses of the interaction of this strain with
complement proteins will clarify the importance of FhbA expression in FH
binding and in vitro complement inactivation. Infection and serum sensitivity
assays will be used to assess the role of the FH-binding phenotype in innate
immune evasion by TBRF spirochetes.
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Materials and Methods

Bacterial strains and cultivation
Borrelia hermsii strain YOR was isolated in 1964 from a human relapsing fever patient
in Siskiyou County, California (122). Borrelia andersonii isolate MOD-1 was originally isolated
from nymphal Ixodes dentatus ticks in Bollinger County, Missouri (93) (Table 1). B. hermsii and
B. andersonii were cultivated in BSK-H complete media supplemented with 12% and 6% rabbit
serum, respectively, at 37°C in a humidified atmosphere with 5% CO2. Antibiotic selection of
transformant strains was achieved with kanamycin (200 μg ml-1).

Isolation of genomic DNA
Cells from log-phase cultures of wild type B. hermsii strain YOR were collected by
centrifugation (14,000 x g, 15 min, 4°C) and washed twice with phosphate buffered saline (PBS)
(1.37 M NaCl, 27 mM KCl, 100 mM Na2HPO4, 20 mM KH2PO4, pH 7.4). Cells were then
resuspended in TES (50 mM Tris-HCl, pH 8.0; 40 mM EDTA; 25% sucrose) and lysed through
incubation with SDS (2%) and Proteinase K (0.3 mg ml-1) (37°C, 45 minutes). Liquid-liquid
extraction of DNA was performed using phenol/chloroform/isoamyl alcohol (25:24:1) and
centrifugal phase separation. Upon aqueous phase recovery, DNA was precipitated by the
addition of 3 volumes of cold 100% ethanol and 0.1 volume of 3 M sodium acetate (pH 5.2) (30
minutes, -70°C). DNA was collected by centrifugation (14,000 x g, 5 min, 4°C), washed twice
with 70% ethanol, and allowed to air dry at room temperature. DNA was then incubated in TE
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Table 1. Summary of strains used in this study

Strain or Isolate

Source

Comments

B. hermsii YOR
(Bh YOR-wt)

Human, Siskiyou Co.,
CA (122)

Wild type strain

Bh YOR::kan gfp

This study

B. hermsii YOR transformant;
r
bears kan gfp insertion

Bh YORΔfhbA

This study

B. hermsii YOR transformant;
r
bears kan gfp insertion and
fhbA gene deletion

B. andersonii MOD-1

Ixodes dentatus tick,
Bollinger Co., MO (93)

Wild type isolate,
Non-FH-binding
(Marconi, R.T.,
unpublished data)

r
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(10 mM Tris-HCl, pH 8.0; 1 mM EDTA) with RNase (Abgene; 0.03 mg ml-1), 1% SDS, and
Proteinase K (0.3 mg ml-1) for 1 hour at 37°C; extracted and precipitated once again, as above;
and resuspended in water. Quantification was achieved by spectrophotometric measurement of
UV absorbance (A260/A280).

Polymerase chain reaction
Polymerase chain reaction (PCR) was performed using an S1000 Thermal Cycler (BioRad) and template sources that included genomic DNA, plasmid DNA, and bacterial cells.
Preparation of cellular template consisted of collecting and boiling Borrelia cells in water (98°C,
12 minutes), and, following brief centrifugation to remove cellular debris, utilization of
supernatants at 1 μl reaction-1. Genomic and plasmid DNA templates were used at 5.0 and 0.5 ng
reaction-1, respectively. The final volume of each PCR reaction was 20 μl, and primers (Table 2)
were used at constant 15-μM concentrations. For vector construction, Phusion High-Fidelity
Master Mix (Phusion High-Fidelity DNA polymerase (0.02 U µl-1), 200 µm each dNTP, 1.5 mM
MgCl2; New England BioLabs) was used. Phusion-specific cycling conditions were as follows:
98°C, 30 seconds; (98°C, 10 seconds; 60°C, 10 seconds; 72°C, 30 seconds-1.5 minutes) x 35
cycles; 72°C, 5 minutes. All other PCR applications were performed using GoTaq Green Master
Mix (GoTaq DNA polymerase, 200 µm each dNTP, 1.5 mM MgCl2; Promega) and the following
cycling conditions: 94°C, 2 minutes; (94°C, 30 seconds; 53-63.5°C, 30 seconds; 72°C, 30
seconds-2 minutes) x 35 cycles; 72°C, 5 minutes. Amplicons were analyzed by agarose gel
electrophoresis and ethidium bromide staining.

Vector construction
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A suicide vector, designated pFAEV3, was designed to allow stable integration of a
kanamycin resistance (kanr) cassette and gfp into lp200. The integration site consists of a 209-bp
non-coding region residing between the 3' end of fhbA and the 3' end of an oppositely-oriented
hypothetical open reading frame (labeled as ORF dn in Figure 1). Regions of lp200 and gfp and
kanr genes were PCR-amplified from B. hermsii YOR genomic DNA and previously constructed
plasmids as described below. Primers were tailed with appropriate restriction sites as needed to
allow for subsequent cloning procedures (Table 2). First, a 1582-bp region of lp200 was
amplified from genomic DNA using the VC1 and VC2 primers. This amplicon extends from
upstream of fhbA through its stop codon (encompassing the fhbA gene and an upstream
hypothetical ORF; VC2 harbors an NheI site). The 209-bp non-coding region targeted for
insertion was amplified from genomic DNA in two fragments: (i) the 99-bp region immediately
3' of fhbA, using VC3 and VC4 primers (with NheI and SalI restriction sites, respectively), and
(ii) a 625-bp region encompassing the remaining non-coding sequence and a downstream ORF
of unknown function, using VC9 and VC10 primers (with AatII and MluI restriction sites,
respectively). The kanr gene, linked to the constitutively active B. hermsii DAH flgB promoter
(PflgB-kanr), was amplified from pTABhFlgB-Kan (17) (kindly provided by Dr. T. Schwan)
using the VC5 and VC6 primers (with SalI and AscI restriction sites, respectively). gfp was
amplified from pCE320 (51) (kindly provided by Dr. J. Radolf) using the VC7 and VC8 primers
(with AscI and AatII sites, respectively). The kanr and gfp genes were linked to allow for
expression from the kanr cassette. The two genes are separated by 60 bp of sequence derived
from the region upstream of the gfp gene. All amplicons were cut with the appropriate restriction
enzymes (New England Biolabs) and, using standard subcloning techniques, ligated into a
pCR2.1 TOPO backbone (Invitrogen) to yield pFAEV3 (Figure 1A).
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Generation of a B. hermsii YOR fhbA deletion mutant was achieved through allelic
exchange mutagenesis using suicide vector construct pFAEV3ΔfhbA. This vector was derived
from pFAEV3, described above. To construct pFAEV3ΔfhbA, the pFAEV3 vector was subjected
to digestion with NheI, resulting in excision of the coding region of fhbA from the vector
sequence. The construct was then re-ligated to yield the final pFAEV3ΔfhbA vector (Figure 1B).

Transformation of B. hermsii
Plasmids were propagated in NovaBlue Escherichia coli cells (Novagen), purified
(HiSpeed Plasmid Midi Kit; Qiagen) according to manufacturer’s instructions, and linearized
with AhdI and PflfI prior to transformation. Electroporation conditions were adapted from
methods originally developed by Samuels et al. for B. burgdorferi (136). B. hermsii YOR cells
were harvested from a 100-ml, mid-log phase culture by centrifugation (5000 x g, 20 min, 4°C),
washed 3 times with cold EPS buffer (93 mg ml-1 sucrose, 15% glycerol), and suspended in 100
μl EPS buffer containing 25 μg of linearized pFAEV3 or pFAEV3ΔfhbA vector. After 5 min on
ice, the cells were electroporated (0.2 cm cuvette, 2.5 kV, 25 mF, 200 W), transferred to 10 ml of
BSK-H media with 12% rabbit serum, and incubated for 24 hours at 37°C. The culture volumes
were increased to 50 ml with fresh BSK-H medium and supplemented with kanamycin (200 μg
ml-1). Cultures were maintained at 37°C and growth was monitored by darkfield microscopy.
Transformant clones were isolated through limiting dilution. Sequential dilutions
containing, theoretically, 50 to 0.00064 spirochetes were prepared and cultured in sterile 96-well
tissue culture plates (Becton Dickinson) containing 200 μl BSK-H media with 200 μg ml-1
kanamycin per well. These plates were then sealed with adhesive plate covers (EdgeBio) and
incubated at 37°C (5% CO2). Growth was monitored by darkfield microscopy.
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Figure 1. B. hermsii pFAEV3 and pFAEV3ÄfhbA suicide vector maps. Suicide vector
pFAEV3 was constructed to allow for the introduction of a selectable marker (kanr) and
green fluorescent protein (gfp) into a non-coding region of the native B. hermsii linear
plasmid, lp200. The vector map is depicted in Panel A. The primers used to generate the
amplicons for vector construction (VC) are indicated (listed in Table 2). (B) B. hermsii
fhbA deletion vector (pFAEV3ÄfhbA) was derived from pFAEV3, through NheI
digestion, to permit kanrgfp cassette integration and deletion of the fhbA coding region
from lp200.
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gfp

Table 2. Oligonucleotide primers

Primer

Sequence (5' to 3')

VC1

GTCAATGGTATATTAGTTTCAAGTTCTATGACCC

VC2

ACGCGTAAAGTCGACTTAACATATAAATAATACTGATATTAAAATTTATGTAAA

VC3

GCTAGCGTTGATCTTATAAATCAAACTGATGTAAAATCAAAACC

VC4

GTCGACTTAACATATAAATAATACTGATATTAAAATTTATGTAAA

VC5

GTCGACGTTAAAGAAAATTGAAATAAACTTGGACTATGTTAATG

VC6

GGCGCGCCTTAGAAAAACTCATCGAGCATCAAATG

VC7

GGCGCGCCGGGCGAATTCGGCTTATTCC

VC8

GACGTCCTATTTGTATAGTTCATCCATGCCATGTG

VC9

GACGTCCCTGAGAGTATAGGCAGTACTTCAATTACTACC

VC10

ACGCGTCAATTGATATTGATGTGGCGTTGATTTCTAAAATAG

TC1

GTCTACTCTATCTGGGATACTAAAGAGC

TC2

TGTGATTTATTCAATAAAAACAAAAAATTAGATGC

TC3

TTAAGTTTTTAAATATTCCATTATAGTTTCAAAAAAATTGTC

TC4

GAGGCATAAATTCCGTCAGC

TC5

GTCCACACAATCTGCCCTTTC

TC6

GCATTAAGTAAGCGGTTTGTGAGC

F1

ATCAGTGAGCTCGATTTATTCAATAAAAACAAAAAATTAGATGCTGATTTAC

F2

TGATACCTCGAGTTAAGTTTTTAAATATTCCATTATAGTTTCAAAAAAATTG

Abbreviations used in primer designations are as follows: VC=vector construction;
TC=transformation confirmation. Restriction site/sacrificial base tails are indicated by
underlining.
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Growth curve analyses
To assess growth rates, equal numbers of actively growing cells of each B. hermsii YOR
strain were inoculated into fresh medium and maintained at 37°C. Microscopic cell counts of
each culture were conducted daily for seven days (from ten fields under 400X magnification,
using darkfield microscopy) and the average numbers of spirochetes per field of view were
determined at each time point.

Plasmid analysis by pulsed-field gel electrophoresis
Cells from log-phase cultures were collected by centrifugation (6,000 x g, 15 min, 4°C),
washed twice with PBS, and resuspended in TN buffer (50 mM Tris-HCl, pH 8.0; 150 mM
NaCl) to a density of ~1 x 109 cells ml-1. Cell suspensions were warmed to 37°C then mixed with
an equal volume of 1.2% agarose (InCert; FMC). Agarose-cell mixtures were transferred to plug
casters and allowed to solidify at room temperature. To lyse embedded cells, plugs were
sequentially incubated in PK solution (50 mM Tris-HCl, pH 8.0; 50 mM EDTA; 1.5% SDS; 1
mg ml-1 Proteinase K) at 45°C, and TE* wash (10 mM Tris-HCl, pH 8.0; 10 mM EDTA) at
50°C. Plugs were then loaded in 1% agarose gels (SeaKem Gold; Lonza) prepared with 0.5x
TBE buffer (44.5 mM Tris base; 44.5 mM boric acid; 1 mM EDTA, pH 8.0). Electrophoresis
was performed in 0.5x TBE buffer at 14°C using a contour-clamped homogeneous electric field
(CHEF) mapper system (Bio-Rad). Automatic parameters for separation of DNA molecules
between 5 and 200 kb were utilized (calibration factor, 1.00; gradient, 6.0 V/cm; run time, 15:16;
included angle, 120°; initial switch time, 0.22 s; final switch time, 17.33 s; ramping factor,
a=linear). DNA was visualized by ethidium bromide staining.
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Immunoblot analyses
B. hermsii cells were solubilized in reducing sample buffer (0.25 M Tris-HCl, pH 8.0; 4%
SDS; 2% β-mercaptoethanol; 20% glycerol; 0.001% bromophenol blue), fractionated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (200 V, 60 minutes) in 15%
Criterion Tris-HCl precast gels (Bio-Rad), and transferred to polyvinylidene diflouride (PVDF)
by electroblotting (100V, 60 minutes). Immunoblots were blocked in blocking buffer (PBS, 0.2%
Tween 20, 5% nonfat dry milk) for 1 hour, then incubated with primary antibody. Primary
antibodies included mouse anti-FhbA antiserum (1:1000) and mouse anti-FlaB antiserum
(1:400,000), diluted in blocking buffer as indicated. Horseradish peroxidase (HRP)-conjugated
goat anti-mouse immunoglobulin G (IgG) (1:40,000; Pierce) served as the secondary antibody.
Incubations were performed at room temperature for 1 hour, and were followed each time by
PBS-0.2% Tween 20 (PBS-T) wash steps to remove unbound antibody. Detection was based on
the reaction of the HRP conjugate with SuperSignal West Pico chemiluminescent substrate
(Pierce).

Proteinase K digestion of surface proteins
Cells (~3.5 x 108) from log-phase B. hermsii cultures were collected by centrifugation
(5,000 x g, 20 min, 4°C), washed with PBS, and resuspended in PBS with or without Proteinase
K (0.2 mg ml-1). After 1 hour at room temperature, digestion was inhibited by the addition of
phenylmethanesulfonylfluoride (PMSF) (5 ug ml-1). Cells were collected by centrifugation
(14,000 x g, 10 min, room temperature) and subjected to immunoblot analysis, as described
above, to assess FhbA expression at the cell surface. Blots were also screened with anti-FlaB (a
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constitutively expressed flagellar protein) to demonstrate specific digestion of surface-exposed
proteins and to confirm equal sample loading.

Affinity ligand binding immunoblot (ALBI) assays
B. hermsii cell lysates were fractionated by SDS-PAGE under reducing conditions and
transferred to PVDF as described above. After blocking, immunoblots were incubated with
purified human FH (5 ng μl-1; CompTech) in blocking buffer for 1 hour at room temperature,
then washed with PBS-T. Bound FH was detected with goat anti-human FH antiserum (1:1000;
Calbiochem) followed by HRP-conjugated rabbit anti-goat IgG (1:40,000; Pierce). Incubations
were performed in blocking buffer at room temperature for 1 hour, and blots were washed
between incubation steps. Detection was based on chemiluminescence.

Whole-cell adsorption of FH and IFA
To assess binding of FH by intact spirochetes, whole-cell FH adsorption assays were
performed. Cells were harvested from 5-ml, mid-log phase cultures by centrifugation (5000 x g,
10 min, 4°C), washed with cold PBS, and resuspended in 100 μl PBS (supplemented with 1 mM
MgCl and 0.15 mM CaCl). The cell suspensions were then incubated with purified human FH
(0.525 mg ml-1) for 1 hour at room temperature. Following extensive washing with PBS, cells
were recovered by centrifugation (3000 x g, 10 min, room temperature) and FH adsorption was
assessed by both immunoblot analysis and immunofluorescence assay (IFA). Immunoblot
analyses were performed as described above: First, cells were solubilized in reducing sample
buffer, fractionated by SDS-PAGE, and transferred to PVDF. The immunoblots were then
blocked and screened with goat anti-human FH antiserum (1:1000) followed by HRP-conjugated
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rabbit anti-goat IgG (1:40,000). Washing was performed between each step, and detection was
achieved through chemiluminescence. For IFA, cells, adjusted to a density of ~7.0 x 106 ml-1 in
PBS, were spotted onto slides (Superfrost Plus; Fisher) and allowed to dry. The slideimmobilized cells were blocked with 3% bovine serum albumin (BSA) in PBS-T, then probed
with goat anti-human FH antiserum at a dilution of 1:5000. The slides were washed three times
with PBS-T, then incubated with Alexa Fluor 568-conjugated rabbit anti-goat IgG (1:200;
Invitrogen). All antisera were diluted in PBS-T with 3% BSA, and incubations were performed
in darkened, humidified chambers for 1 hour at room temperature. After a final wash step, cover
slips were mounted using an antifade reagent (ProLong Gold; Invitrogen), and the immobilized
cells were visualized by fluorescence microscopy.

Plasminogen binding assay and ELISA
Cells from actively growing cultures of each B. hermsii strain were collected by
centrifugation (5000 x g, 15 min, 4°C) and washed with PBS. Cells were suspended in carbonate
coating buffer (27.6 mM sodium carbonate, 18.9 mM sodium bicarbonate, pH 9.6) to an adjusted
concentration of ~1 x108 cells ml-1, then incubated in 96-well ELISA plates (Costar 3590;
Corning) at 100 μl well-1 overnight at 4°C. Plate-immobilized cells were blocked with 5% BSA
in PBS-T, then incubated with plasminogen (10 μg ml-1 in 5% BSA-PBS-T; Sigma) for 1 hour at
room temperature. Control wells were (i) coated with wild type B. hermsii YOR cells and
incubated with 5% BSA-PBS-T only, and (ii) left uncoated, then blocked and incubated with
plasminogen. To remove unbound plasminogen, plates were washed three times with PBS-T
using an automated ELx405 Microplate Washer (Bio-Tek). To assess plasminogen binding by
enzyme-linked immunosorbent assay (ELISA), plates were screened with goat anti-plasminogen
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antiserum (1:1000) and then washed as above. Bound primary antibodies were detected with
HRP-conjugated rabbit anti-goat IgG (1:40,000) and 2,2'-azino-bis(3-ethylbenzthiazoline-6sulphonic acid) (ABTS) chromogenic substrate. All incubations were performed in 5% BSAPBS-T for 1 hour at room temperature. Absorbance was read at 405 nm using an ELISA plate
reader (ELx808; Bio-Tek).

C3b cleavage assay
To assess the role of FH binding in C3b inactivation by B. hermsii, cells (1 x 108) of
each B. hermsii strain were harvested from mid-log phase cultures by centrifugation (3000 x g,
15 min, 4°C). Cells were washed with cold PBS, suspended in PBS (with 10mM MgCl2) (50 μl),
and incubated with or without purified human FH (2 μg ml-1; 37°C; 1 hour). After thorough
washing, cells were incubated in PBS (with 10mM MgCl2) (20 μl) with purified factor I (150 ng;
Calbiochem) and C3b (250 ng; CompTech) for 2 hours at 37°C. As a control, FH (100 ng), FI
(150 ng), and C3b (250 ng) were co-incubated in solution. Following sedimentation of cells,
reaction supernatants were mixed with reducing sample buffer, fractionated by SDS-PAGE, and
blotted as described above. The presence of C3b cleavage products was assessed by immunoblot
analysis using goat anti-human C3 antiserum (1:800; CompTech), HRP-conjugated rabbit antigoat IgG (1:40,000), and chemiluminescence.

Serum sensitivity assay
Aliquots of log-phase cultures of B. hermsii strains and B. andersonii isolate MOD-1 (a
serum sensitive control) were incubated at 37°C in 50% normal human serum (NHS) (Valley
Biomedical) or heat-inactivated (56°C, 30 minutes) human serum (hiNHS). After 2, 6, and 24
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hours, cells were stained using the LIVE/DEAD BacLight Bacterial Viability Kit (Invitrogen)
according to manufacturer’s instructions, and examined by fluorescence microscopy (ten fields,
400X magnification) to assess survival. Data are presented as percent survival, calculated as:
[number alive/(number alive + number dead)] x 100.

Cell-surface deposition of C9
Cells (1 x 106) from mid-log phase cultures of B. hermsii YOR strains and B. andersonii
isolate MOD-1 were collected by centrifugation (5000 x g, 15 min, 4°C), washed with cold PBS,
and incubated in 10% NHS or hiNHS for 30 min at 37°C. Following extensive washing, cells
were immobilized onto ELISA plates in carbonate coating buffer as described above and
screened with goat anti-C9 antiserum (1:1000; CompTech) and HRP-conjugated rabbit anti-goat
IgG (1:40,000). Detection was achieved using ABTS chromogenic substrate. Blocking and
incubations were performed in 1% BSA-PBS-T. All other ELISA conditions were as described
above.

Infection analyses
Infectivity was assessed by subcutaneous needle inoculation of C3H/HeJ mice (n=5) with
5 x 104 spirochetes in BSK-H media. One uninfected mouse of the same cohort was maintained
as a control. Blood samples were collected from tail nicks performed 0, 3, 4, 7, 10, 14, 18, and
42 days post-infection and were mixed with sodium citrate buffer (0.15 M trisodium citrate in
water) at a 9:1 ratio to prevent clotting. The presence of spirochetes at each time point (with the
exception of Day 42) was assessed visually by darkfield microscopy of diluted blood samples
(1:20 in PBS; 5 μl). Data are presented as number of spirochetes ml-1 blood, calculated using the
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following conversion factor: number of spirochetes 400X field-1 x (2.5 x 103) = number of
spirochetes ml-1. Additionally, at each time point, undiluted blood (6 μl) was added to BSK-H
media (supplemented with rifampicin, fosfomycin, and amphotericin B) and incubated at 37°C.
Cultures were microscopically assessed for spirochete growth after 3 weeks of incubation.

Serological analyses and generation of recombinant protein
Blood was collected at 4 weeks post-inoculation and serum (―infection serum‖) was
harvested using standard centrifugal methods. To assess murine seroconversion, ELISA plates
were coated with a suspension of wild type B. hermsii YOR cells in carbonate buffer, as
described above. Plates were blocked with 1% BSA-PBS-T and wells were screened in triplicate
with a dilution series (from 1:50 to 1:109,350) of infection serum from each mouse. After
washing, bound anti-Borrelia IgG was detected using HRP-conjugated goat anti-mouse IgG
(1:20,000) and ABTS chromogenic substrate. Incubations were performed in 1% BSA-PBS-T.
All other ELISA conditions were as described above.
To determine whether sera of infected mice was reactive against FhbA, recombinant B.
hermsii YOR FhbA (r-FhbA) was generated, immunoblotted as described above, and screened
with infection sera (pooled by experimental group; 1:2500). Detection was achieved using goat
anti-mouse IgG (1:40,000) and chemiluminescence. To generate the r-FhbA protein utilized in
this assay, the coding sequence of fhbA (exclusive of the signal sequence) was PCR-amplified
from B. hermsii YOR genomic DNA using primers tailed by restriction sites compatible with
subsequent cloning steps (F1 and F2; Table 2). Amplicons were gel purified (QIAquick Gel
Extraction Kit; Qiagen), digested with SacI and XhoI, and ligated into the pET45b(+) vector
(Novagen) through standard methods. The resulting plasmids were propagated according to
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manufacturer’s instructions in NovaBlue and BL21 (DE3) E. coli cells (Novagen). Following
IPTG induction, recombinant proteins, bearing 1.7 kDa N-terminal His-Tags, were purified from
E. coli cell lysates using a His-Bind purification kit (Novagen) as directed by the manufacturer.

Microscopy
All microscopy was performed using an Olympus BX51 microscope fitted with a DP71
camera (Olympus) and fluorescein and rhodamine filter sets. Darkfield and fluorescence
micrographs were recorded using DP Controller 3.1.1.267 software (Olympus).
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Results

Generation of B. hermsii YOR transformants
To generate a B. hermsii strain that harbors a selectable marker (kanr) and constitutively
expresses a fluorescent marker (gfp) (Bh YOR::kanrgfp), the pFAEV3 vector was constructed
(Figure 1A) and electroporated into B. hermsii YOR. Transformation resulted in the insertion of
a kanr-gfp cassette into a non-coding sequence located on lp200 between the wild type fhbA gene
and a hypothetical ORF (Figure 2A). The B. hermsii YOR fhbA deletion mutant (Bh YORΔfhbA)
was generated using the pFAEV3ΔfhbA vector (Figure 1B), which mediated deletion of the fhbA
coding region from lp200 and integration of the kanr-gfp cassette as described above (Figure
2A). Clonal populations of Bh YOR::kanrgfp and Bh YORΔfhbA were derived through limiting
dilution.
PCR analyses (Figure 2A) and fluorescence microscopy (Figure 2B) were performed to
verify successful transformation. All transformant spirochetes observed by fluorescence
microscopy produced GFP, although some cell-to-cell variability in signal intensity was
observed (data not shown).

Characterization of plasmid composition and growth kinetics
Electroporation of B. burgdorferi often results in the loss of some plasmids (91, 124,
132). Since Borrelia plasmids encode genes required for survival in mammalian and arthropod
hosts, plasmid loss can influence the interpretation of mutagenesis studies. To determine if
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Figure 2. PCR- and microscopy-based verification of allelic exchange. Panel A
presents a schematic depicting lp200 from wild type B. hermsii YOR (Bh YOR-wt) and B.
hermsii transformant strains (Bh YOR::kanrgfp, Bh YORÄfhbA) after mutagenesis.
Locations of primer targets for PCR used to confirm transformation (TC primers) are
indicated. The ethidium bromide-stained amplicons obtained through PCR analyses are
shown. Primer sequences can be found in Table 2. (B) Fluorescence microscopy (FM)
was performed to screen strains for GFP production during in vitro culture. Darkfield
microscopy (DM) was used to confirm the presence of spirochetes in the selected fields.
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Bh YORÄfhbA

genetic manipulation of B. hermsii YOR resulted in plasmid loss, the plasmid compositions of
Bh YOR::kanrgfp and Bh YORΔfhbA were assessed by pulsed-field gel electrophoresis (PFGE).
This approach revealed the plasmid profiles of the parental and transformant strains to be
indistinguishable (Figure 3). Additionally, growth curve analyses demonstrated that Bh
YOR::kanrgfp and Bh YORΔfhbA grow normally in culture (Figure 4), suggesting that neither
insertion of the kanrgfp cassette nor deletion of fhbA interfere with in vitro viability.

Analyses of FhbA/factor H-binding protein expression
Expression and cell-surface presentation of FhbA were assessed by immunoblot analyses
coupled to Proteinase K digestion. Following incubation either with Proteinase K or with PBS
alone, cells of each B. hermsii YOR strain were solubilized, fractionated by SDS-PAGE, and
probed with anti-FhbA antiserum. Bh YOR::kanrgfp was found to express FhbA after treatment
with PBS, but not after digestion with Proteinase K, demonstrating that kanrgfp cassette insertion
does not interfere with cell-surface expression of the adjacent fhbA gene (Figure 5A). Bh
YORΔfhbA, however, failed to express FhbA under control or experimental conditions,
suggesting elimination of FhbA expression in this strain (Figure 5A). Factor H affinity ligand
binding immunoblot (FH ALBI) analysis was performed to further assess factor H-binding
protein expression. Untreated B. hermsii cells were solubilized, immunoblotted, and incubated
with purified human FH. Proteins capable of retaining FH were detected using anti-FH
antiserum. Wild type B. hermsii YOR (Bh YOR-wt) and Bh YOR::kanrgfp bound FH to an ~20.5
kDa protein presumed to be FhbA, while no Bh YORΔfhbA proteins capable of binding FH were
identified (Figure 5B). For both assays, identical blots were screened with antiserum against the
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Figure 3. Assessment of plasmid content by PFGE. The plasmid content of each B.
hermsii YOR strain was assessed using pulsed-field gel electrophoresis (PFGE) and
ethidium bromide staining. DNA size standards (in kb) are indicated to the left of the
panel.
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Figure 4. Growth curve analyses. Growth curves for each B. hermsii YOR strain were
determined through microscopic cell counts (400X magnification) of equivalently
inoculated cultures each day for seven days. The growth curves of Bh YOR::kanrgfp and
Bh YORÄfhbA were compared to the growth curve of the parental wild type strain (Bh
YOR-wt) in separate experiments, presented in Panel A and Panel B, respectively.
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Figure 5. Analyses of FhbA expression by immunoblot and FH ALBI. FhbA
expression was assessed (A) by immunoblot analysis of spirochetes that were pre-treated
with or without Proteinase K, and (B) by FH ALBI analysis. The ALBI assay was
performed by incubating immunoblots of lysates from untreated cells with purified
human FH. After washing, FH bound by membrane-immobilized B. hermsii proteins was
detected using anti-FH antiserum. In both assays, identical blots were screened with antiFlaB antiserum to confirm equal sample loading. For the Proteinase K assay, this control
additionally demonstrated specific digestion of surface-exposed proteins.
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periplasmic flagellar protein FlaB to demonstrate equal loading of samples and, for the
Proteinase K assay, specific digestion of surface-exposed proteins.

Analysis of the role of FhbA in whole-cell adsorption of FH
Although previous studies (78, 106) suggest that FhbA is the only factor H-binding
protein produced by B. hermsii, the contribution of FhbA to the factor H-binding phenotype has
not been directly assessed. To evaluate this under biologically relevant conditions, we incubated
whole spirochetes with purified human FH. After washing, cell surface adsorption of FH was
assessed. When screened by immunofluorescence assay (IFA), Bh YOR-wt and Bh
YOR::kanrgfp cells demonstrated cell-surface FH adsorption, while FH was not detected in
association with Bh YORΔfhbA cells (Figure 6A). Screening of FH-treated cells by immunoblot
analysis also showed that Bh YOR-wt and Bh YOR::kanrgfp, but not Bh YORΔfhbA, adsorb FH
from human serum (Figure 6B).

Analysis of C3b inactivation
Wild type B. hermsii cells that have been pre-incubated with FH are able to inactivate
C3b in a factor I-mediated manner (106). To assess whether this ability is lost with abrogation of
FH binding, strains of B. hermsii YOR were incubated with or without FH, washed, and then
incubated with C3b in the presence of factor I. None of the strains displayed inherent C3bcleavage ability, and only intact C3b α’ and  chains (which migrate separately under reducing
conditions) were detected in the reaction mixtures of non-FH-adsorbed cells (Figure 7). When
pre-incubated with FH, however, the FhbA-expressing Bh YOR-wt and Bh YOR::kanrgfp strains
degraded C3b. This was evidenced by the accumulation of α’43 and α’68 C3b cleavage products
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Figure 6. Assessment of factor H binding through whole-cell adsorption assays.
Intact cells of each B. hermsii YOR strain were incubated with purified human FH. To
detect surface-adsorbed FH, the cells were analyzed by (A) immunofluorescence assay
(DF=darkfield microscopy, FM=fluorescence microscopy), and (B) immunoblot analysis.
Screening for both assays was performed using anti-human FH antiserum and appropriate
secondary antibodies. During immunoblot analysis, an identical blot was screened with
anti-FlaB antiserum to demonstrate equal loading of samples.
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in the respective reaction mixtures (comparable to the cleavage products generated by the
purified FH control). In contrast, Bh YORΔfhbA failed to cleave C3b regardless of FH preincubation (Figure 7).

FhbA expression and the binding of plasminogen by B. hermsii YOR
Binding of plasminogen/plasmin by Borrelia may play an important role in invasion and
dissemination within the host (37, 117). In addition to binding FH, B. hermsii FhbA has been
shown to bind other host-derived serum proteins including plasminogen (76). The effect of fhbA
deletion on B. hermsii plasminogen-binding ability was assessed by ELISA. Although slightly
decreased levels of bound plasminogen were detected for Bh YORΔfhbA as compared to Bh
YOR-wt, all strains bound plasminogen at levels well above background (as established by
controls) (Figure 8).

Comparative analyses of serum sensitivity and C9 deposition
To assess the role of FhbA in complement evasion in vitro, B. hermsii wild type and
transformant strains were incubated with either normal, complement-active serum (designated
NHS) or heat-inactivated human serum (hiNHS). Serum sensitive B. andersonii isolate MOD-1
served as a control. At 2, 6, and 24 hours, the bacteria were examined for viability using
BacLight LIVE/DEAD staining. Consistent with previous results (76), Bh YOR-wt remained
resistant to killing in normal human serum, as did transformant strain Bh YOR::kanrgfp (Figure
9A). In contrast, B. andersonii was largely killed within 2 hours, confirming the complement
activity of the normal serum. Despite being unable to inactivate C3b through FH/FI-mediated
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Figure 7. Analysis of C3b cleavage. Cells of each B. hermsii YOR strain were pretreated with or without FH, as indicated, prior to incubation with factor I and C3b. As a
control, FH, factor I, and C3b were co-incubated in solution. Following removal of cells,
the reaction mixtures were immunoblotted and screened with anti-C3 antiserum.
Expected sizes of the C3b á’ and â chains, as well as the factor-I mediated C3b cleavage
products á’43 and á’68, are indicated to the right of the panel.
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Figure 8. Analysis of the effects of fhbA deletion on B. hermsii plasminogen binding.
Cells of each B. hermsii YOR strain were immobilized into 96-well plates, incubated
with plasminogen, and screened by ELISA to detect bound plasminogen. Controls
consisted of Bh YOR-wt cells incubated with BSA alone (No plasminogen) and uncoated
wells incubated with plasminogen (No cells). All samples were run in triplicate. Error
bars represent standard deviation.
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cleavage (Figure 7), Bh YORΔfhbA did not display increased serum sensitivity and remained
resistant to killing out to 24 hours (Figure 9A).
Although both Bh YORΔfhbA and B. andersonii MOD-1 lack the ability to bind FH, the
latter displayed a high degree of serum sensitivity while Bh YORΔfhbA remained serum
resistant. To explore this discrepancy, an assay was performed to assess cell-surface deposition
of complement protein C9, an integral component of the cytolytic membrane attack complex
(MAC), following incubation in serum. Cells were incubated in 10% NHS or hiNHS, washed,
and screened by ELISA using anti-C9 antiserum. Consistent with its high degree of serum
sensitivity, B. andersonii MOD-1 underwent significant C9 deposition in complement-active
serum, while minimal deposition was seen on the FH-binding, serum resistant strains Bh YORwt and Bh YOR::kanrgfp (Figure 9B). Interestingly, Bh YORΔfhbA did not undergo increased C9
deposition, suggesting a molecular basis for its ability to resist destruction in complement-active
serum.

Demonstration of the ability of B. hermsii YOR transformants to infect and persist in mice
To determine if B.hermsii YOR transformant strains are infectious, mice (n=5) were
needle inoculated and blood was collected at 0, 3, 4, 7, 10, 14, 18, and 42 days post-inoculation.
Spirochetemia was measured by microscopic counts of organisms in 5 μl blood (diluted 1:20 in
sodium citrate anticoagulant and PBS). All B. hermsii YOR strains were infectious and reached
comparable levels in the bloodstream (Figure 10A). Only a single spirochetemic peak, on Day 4
of infection, was observed for all infecting strains. However, Bh YOR-wt and Bh YOR::kanrgfp
persisted through Day 14, and Bh YORΔfhbA through Day 18, in individual animals, as
evidenced by re-cultivation of spirochetes from cultured blood samples (Table 3). All mice
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Figure 9. Serum sensitivity analyses and assessment of C9 cell surface deposition.
(A) Cells of B. andersonii MOD-1 (serum sensitive control) and each B. hermsii YOR
strain were incubated with 50% normal human serum (NHS; closed circles) or heatinactivated human serum (hiNHS; open circles). Cell viability was assessed after 2, 6,
and 24 hours of incubation using BacLight LIVE/DEAD staining and fluorescence
microscopy. The mean percent survivals were calculated from counts of ten fields (400X
magnification) per strain at each time point. (B) Deposition of complement component
C9 on cells of B. andersonii MOD-1 (control) and B. hermsii strains was assessed by
ELISA. Following incubation in 10% NHS or hiNHS, cells were immobilized into
ELISA plates and screened with goat anti-C9 antiserum and an appropriate secondary
antibody. Samples were run in triplicate, with error bars representing standard deviation.
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developed significant and equivalent anti-B. hermsii IgG titers, indicating seroconversion (Figure
10B). To verify the integrity of the infecting strains, an attempt was made to PCR amplify fhbA
from each strain re-isolated from murine blood (obtained at peak spirochetemia, 4 days postinoculation) using primers TC2 and TC3 (Table 2). Amplicons were generated from each Bh
YOR-wt and Bh YOR::kanrgfp isolate, but not from any isolate of Bh YORΔfhbA (Figure 11A).
Additionally, screening of immunoblots of recombinant B. hermsii YOR FhbA (r-FhbA) with
pooled infection sera from each experimental group demonstrated that an FhbA-specific IgG
response was generated during infection with Bh YOR-wt and Bh YOR::kanrgfp, but not during
infection with Bh YORΔfhbA (Figure 11B).

Demonstration of the in vivo stability of spirochetal GFP expression
To determine if the Bh YOR::kanrgfp and Bh YORΔfhbA transformant strains stably
produce GFP during infection and upon re-isolation from mammals, fluorescence microscopy
was performed on spirochetes recultivated from mouse blood in the absence of kanamycin (data
not shown) and on diluted murine blood samples obtained during infection (Figure 12). All
transformant spirochetes observed by microscopy produced GFP, demonstrating that GFP
production by these strains is stable in vivo and upon release of antibiotic selection.
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Figure 10. Analysis of infectivity and persistence in mice. Mice (n=5) were infected
with B. hermsii YOR strains by needle inoculation. (A) At days 3, 4, 7, 10, 14, and 18
post-inoculation, peripheral blood samples were obtained and assessed for the presence of
spirochetes by darkfield microscopy. Data are presented as number of spirochetes per ml
of blood for each infecting strain at each time point. Calculations are detailed in the text.
Error bars represent standard deviation. (B) To compare humoral immune responses
elicited by each infecting strain (as indicated), murine anti-B. hermsii IgG titers were
determined using serum harvested from mice 4 weeks post-inoculation and ELISA
analysis. Whole cells of wild type B. hermsii YOR (Bh YOR-wt) served as the antigenic
target. Experimental groups were compared based on geometric means (grey bars) of
titers calculated for individual mice (triangles) at 1/3 maximum absorbance (OD405).
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Figure 11. Serological and PCR-based analyses of infectious B. hermsii strains. (A) All B.
hermsii YOR strains recultivated from the blood of individual mice (A-E, indicated above the
panel) were analyzed by PCR using fhbA-specific primers (TC2/TC3; Table 2). Associated
ethidium-bromide stained amplicons are shown. (B) The ability of each strain to elicit an FhbAreactive IgG response during murine infection was assessed by screening identical r-FhbA
immunoblots with infection sera (pooled by infecting strain, as indicated below each panel)
obtained from mice 4 weeks post-inoculation.
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Figure 12
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Figure 12. Demonstration of in vivo GFP production. Darkfield and fluorescence
microscopy (DF and FM) were used to analyze spirochetal GFP production in diluted
blood samples obtained from infected mice four days post-inoculation.
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Discussion

Genetic manipulation techniques have been used to study multiple aspects of the biology
and virulence of the LD spirochete B. burgdorferi. Prior to this study, however, there has been
only a single report of successful genetic manipulation of a TBRF spirochete (17). Battisti and
colleagues inactivated the vtp gene, which encodes the variable tick protein (Vtp), by replacing
vtp with an antibiotic resistance cassette through site-directed allelic exchange. This study was
performed using B. hermsii DAH clone 2E7 (a GGI strain) and standard methods of electrotransformation. While Vtp was found to be nonessential for infectivity in mammals, this earlier
report served as the first demonstration that foreign DNA can be introduced in a site-specific
manner into a TBRF spirochete.
In this work, we generated a clonal population of B. hermsii strain YOR that harbors a
selectable marker (kanr) and constitutively expresses a fluorescent marker (gfp). To achieve this,
a suicide vector, pFAEV3, was constructed and electroporated into B. hermsii YOR. A major
obstacle in the genetic manipulation of B. burgdorferi is that infectious strains often have very
low transformation efficiencies (1-1000 transformants μg-1 DNA (91, 136), as opposed to >107
μg-1 DNA for E. coli) for reasons that remain unclear. The limitations imposed by this
intractability can generally be overcome by use of very large amounts of transforming DNA (up
to 50 μg per 109 cells) (166). Here, because the transformation efficiency of B. hermsii was
unknown, plasmid DNA was utilized at a high concentration of 25 μg per reaction (~109 cells).
Transformation of B. hermsii YOR resulted in the insertion of the kanr-gfp cassette into a non52

coding sequence of lp200 between the fhbA gene and a hypothetical ORF. lp200 was chosen to
harbor the integration site due, in part, to the availability of sequence for this plasmid and its
wide distribution and stability among B. hermsii isolates (78, 79).
In our initial attempts to perform genetic transformation of B. hermsii, we employed the
spectinomycin-streptomycin resistance gene aadA, fused to a B. burgdorferi flgB promoter (59),
for selection. Although the utility of this cassette in B. burgdorferi has been well established (50,
59, 84), multiple (>20) individual attempts to generate B. hermsii YOR transformants using this
resistance cassette were uniformly unsuccessful. Although B. burgdorferi B31 and B. hermsii
DAH flgB promoters are very similar (94% sequence identity), the use of certain foreign
promoters has been shown to decrease expression of antibiotic resistance genes in Borrelia (21).
Therefore, we reconstructed our vector in order to incorporate a kanamycin resistance gene
(kanr) (used with success in B. hermsii previously (17)) linked to a native B. hermsii DAH flgB
promoter. When the remodeled pFAEV3 vector was subsequently used in transformation
experiments, 33% of electroporation reactions yielded positive transformants. It is not clear if the
promoter element or the kanr resistance gene (or both) enabled successful transformation, but no
conditions beyond those were altered between experimental attempts.
Having successfully established a protocol for transformation of B. hermsii YOR, we
reasoned that similar methods could be extended to study specific B. hermsii virulence
mechanisms. Of particular interest was the immune evasive mechanism of FH binding. Many
pathogens produce proteins able to bind FH at the cell surface, thereby exploiting its function as
a negative regulator of the complement cascade (61, 74, 112, 113, 140). In several pathogenic
spirochetes, including the Borrelia, FH-binding ability appears to correlate with complement

53

resistance and, potentially, infective potential (23, 76, 86, 101, 108, 131). However, direct
evidence of the role of FH-binding in the Borrelial disease process is lacking.
B. hermsii is an ideal model system in which to study this process. For B. burgdorferi,
which produces five factor H-binding proteins (CspA; CspZ; and OspE family proteins BBN38,
BBL39, and BBP38), complete elimination of the FH-binding phenotype would require
inactivation of multiple genes on various plasmids. While cspA (bbA68) and cspZ (bbh06) have
been inactivated individually (23, 36), the inactivation of five Borrelial genes simultaneously is
beyond the scope of current techniques. In contrast, B. hermsii produces only one factor Hbinding protein, FhbA. fhbA is a single copy gene with no known paralogs, is transcribed as a
monocistronic message, and is separated from putative upstream and downstream ORFs by >100
bases (78). Collectively, these factors recommended fhbA as a highly useful and feasible target
for mutagenesis.
Genetic manipulation methods were repeated to generate a B. hermsii YOR fhbA deletion
mutant (Bh YORΔfhbA) using the pFAEV3ΔfhbA allelic exchange vector and electroporation.
Transformation with this vector resulted in deletion of the fhbA coding region from lp200 and
integration of the kanr-gfp cassette through a double-crossover event.
Following transformation and recovery in liquid culture, clonal populations of Bh
YOR::kanrgfp and Bh YORΔfhbA were derived through limiting dilution. For unknown reasons,
efforts to generate clonal populations using the standard sub-surfacing plating methods
developed for B. burgdorferi (136) were not successful. PCR analyses and fluorescence
microscopy were performed to verify successful transformation and GFP expression.
An additional challenge in the genetic manipulation of B. burgdorferi is loss of
endogenous plasmids that encode proteins required for survival in either tick or mammalian
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hosts (91, 124, 132). In B. burgdorferi, plasmid content is typically assessed by PCR using
plasmid-specific primer sets (87, 105, 124). However, while the sequence of the B. hermsii
DAH chromosome is available, sequences for the plasmids are not. Hence, plasmid-specific PCR
could not be applied for this purpose here. Instead, plasmid profiles of the B. hermsii YOR wild
type and transformant strains were assessed by pulsed field gel electrophoresis (PFGE). We did
not observe any differences in plasmid profiles between strains, although it is possible that some
B. hermsii plasmids were not discerned by this approach due to size similarities and co-migration
patterns. Additionally, growth curve analyses demonstrated comparable growth rates between
transformant and parental strains. This verified that neither insertion and expression of kanrgfp
nor deletion of fhbA interfere with in vitro viability, and provided additional evidence that
plasmids necessary for growth were not lost during transformation.
To analyze expression and cell-surface presentation of FhbA, cells of each strain were
incubated with or without Proteinase K, then fractionated by SDS-PAGE. Immunoblot analyses
using antiserum directed against FhbA demonstrated that while Bh YOR::kanrgfp expressed
FhbA at the cell surface, FhbA was not expressed by Bh YORΔfhbA. To further assess
FhbA/factor H-binding protein expression, untreated cell lysates were fractionated by SDSPAGE and analyzed by FH ALBI. This assay detects membrane-immobilized spirochetal
proteins capable of binding FH. As anticipated, Bh YOR-wt and Bh YOR::kanrgfp bound FH to a
single ~20 kDa protein consistent in size with FhbA, while no proteins produced by the fhbA
deletion mutant displayed FH-binding ability.
One limitation of the FH ALBI assay as performed here is that reducing and denaturing
conditions may alter sample properties and conformation prior to analysis. Therefore, it is
possible that certain proteins capable of binding FH under nondenaturing, physiologic conditions

55

may not be detected by this method. The Bh YORΔfhbA mutant strain provides a unique
opportunity to examine physiologic B. hermsii FH binding through a whole cell adsorption
assay. Here, cells of each strain were incubated in purified human FH, washed, then screened for
cell-surface FH adsorption using anti-FH antibodies. Both IFA and immunoblot screening
methods demonstrated that FhbA-positive, but not FhbA-negative, cells adsorbed FH to the cell
surface. This result provides the first direct evidence that FhbA is B. hermsii’s sole factor H
binding protein and that its deletion results in complete loss of the FH-binding phenotype.
Consistent with this, Bh YORΔfhbA was unable to cleave and inactivate complement protein
C3b in the presence of factor I and following incubation with factor H. This almost certainly is a
functional consequence of its inability to bind FH. Data here and in previous studies demonstrate
that B. hermsii YOR lacks inherent C3b cleavage abilities (e.g., through production of
proteases), but rather binds FH in a functionally active manner that permits cofactor activity in
the factor-I mediated cleavage of C3b (106).
In addition to FH, FhbA has been shown to interact with multiple host ligands including
plasminogen (76). To assess the contribution of FhbA to whole-cell plasminogen binding, plateimmobilized cells of each strain were incubated with plasminogen, washed, and screened using
anti-plasminogen antibodies. This binding assay revealed that levels of retained plasminogen
appeared marginally decreased for Bh YORΔfhbA as compared to Bh YOR-wt; however, all
strains demonstrated clear plasminogen-binding ability as compared to controls. This suggests
that although FhbA may contribute to cumulative plasminogen acquisition by B. hermsii YOR,
alternate mechanisms likely compensate for the loss of FhbA expression. Therefore, an attempt
to identify additional B. hermsii plasminogen-binding proteins may be warranted.
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Previous studies have demonstrated that B. hermsii high passage strain REN, which lacks
fhbA, exhibits increased sensitivity to killing in serum and an inability to persist in, but not to
infect, mice (76). To examine whether deletion of fhbA in strain YOR similarly impacts serum
resistance, all B. hermsii YOR strains, as well as B. andersonii MOD-1 (a non-FH-binding,
serum sensitive control strain) were incubated in normal, complement-active human serum
(NHS) or in serum rendered complement-inactive through heat treatment (hiNHS). Intriguingly,
while B. andersonii was rapidly killed in complement-active NHS, all B. hermsii YOR strains
exhibited a high degree of serum resistance in NHS out to 24 hours. Analyses of cell-surface C9
deposition on similarly treated cells provided insight into the molecular basis of these
observations, as B. andersonii MOD-1 was found to bear high levels of membrane-associated
C9, a terminal MAC component. All B. hermsii strains, however, including Bh YORΔfhbA, were
spared such deposition. Consistent with these results, infection analyses in C3H/HeJ mice
demonstrated Bh YORΔfhbA to be fully infectious, generating spirochetemias and eliciting antiB. hermsii IgG responses equivalent to Bh YOR-wt and Bh YOR::kanrgfp. Unlike FhbA-negative
B. hermsii strain REN, which reached high levels during initial infection then was prematurely
cleared, Bh YORΔfhbA was cultured from the blood of individual mice at Day 18, a time point
beyond when Bh YOR-wt and Bh YOR::kanrgfp had been eliminated from their respective hosts.
Although only moderately reliable in the clinical setting (5, 62, 116, 137, 154), direct
microscopic examinations of peripheral blood samples are widely used to monitor RF infections
under laboratory conditions (4, 65, 95, 152) where disease kinetics can be anticipated and
assessed over a broad temporal range. Nonetheless, sample size inherently constrains the
sensitivity of this method (46), and the detection limit here was approximately 4 x 103
spirochetes ml-1 murine blood. Direct blood culturing, when successful, offers increased

57

detection sensitivity (here, a theoretical limit of 167 spirochetes ml-1 blood), but not quantitative
assessment of spirochete burden. Coupling of these assays allowed us to assess and compare
various aspects of infections produced by each B. hermsii strain. Although highly sensitive PCRbased molecular diagnostic techniques for RF have been developed (typically targeting the 16S
rRNA or glpQ genes, or the rrs–rrlA intergenic spacer region (5, 116, 137)), they are cost- and
labor-intensive and thus are not typically employed for routine spirochetemic monitoring.
Because limiting dilution is not a standard method of establishing clonal populations in
the Borrelia, additional assays were performed to ensure that the observed infections were in fact
caused by transformant populations and not by the rare wild type variant that was able to
proliferate in the in vivo environment. PCR analysis demonstrated that fhbA could be amplified
from all strains recultivated from Bh YOR-wt- and Bh YOR::kanrgfp- infected mice, but not
from strains recultivated from mice infected with Bh YORΔfhbA. Consistent with this, sera from
mice infected with Bh YOR-wt and Bh YOR::kanrgfp were reactive against recombinant FhbA
protein, but sera from YORΔfhbA-infected mice and from uninfected mice were nonreactive.
Stable expression of GFP was observed for all transformant strains both in murine blood samples
during infection and in culture (without kanamycin selection) following recultivation from blood.
This provides important confirmation that the gfp insertion is stably maintained in the B. hermsii
genome.
In summary, Bh YORΔfhbA does not produce FhbA or bind factor H. Because it lacks
FH-binding abilities, this strain is unable to cleave and inactivate C3b in solution. However, Bh
YORΔfhbA is not susceptible to C9 deposition, as is reflected in its high degree of serum
resistance, and is infectious and able to persist in a murine host. This suggests that B. hermsii can
evade complement activation via one or multiple non-FH-mediated mechanisms. Such potential
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mechanisms may involve binding or production of additional factors capable of negatively
regulating the complement cascade. Although pathogen exploitation of FH in particular has been
heavily scrutinized, studies have identified a plethora of additional evasive mechanisms
involving host complement regulatory proteins (89). These proteins include both early
(complement receptor type 1 (CR1), membrane cofactor protein (MCP), decay-accelerating
factor (DAF)) and late (vitronectin, CD-59) regulators of the alternative complement pathway
(Figure 13). Membrane-associated regulators, such as CR1, MCP, DAF, and CD-59, are broadly
distributed across the surfaces of most mammalian host cells, where they act to control local
complement activation along with performing a variety of additional functions. Important fluidphase regulators of alternative complement activation include both FH and vitronectin, soluble
proteins present in host plasma and some body fluids (175). Actions of alternative pathway
regulatory proteins fall into three general groups: inactivation of C3b through factor I-mediated
cleavage, destabilization of the C3bBb C3 convertase, and interference with terminal component
assembly/membrane insertion (110) (Figure 13). Based on the results of the C3b assay presented
here (Figure 7), B. hermsii YOR does not appear to produce endogenous factors that fall into the
first category (i.e., participate in factor I-mediated C3b cleavage). Of particular interest,
however, are the potential roles in B. hermsii complement evasion of vitronectin or a CD-59-like
protein, both of which interact with terminal complement components to prevent MAC
formation (110). The former would represent a novel mechanism in Borrelia (although it is
employed by other pathogens, such as Moraxella catarrhalis (6, 153)), while the latter has been
documented previously in B. burgdorferi (121).
In conclusion, these results collectively suggest that TBRF spirochete B. hermsii YOR
employs an unidentified, FH-independent mechanism of complement evasion that is sufficient
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Figure 13

Alternative Pathway
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C3bBb (C3 convertase)
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Membrane Attack Complex (MAC)
Lysis of Pathogen

Figure 13. Negative regulators of the alternative complement pathway. Fluid-phase
regulator factor H and cell-surface regulators CR1, DAF, and MCP inhibit alternative
complement activation through both cofactor activity in the factor I-mediated cleavage of
C3b and decay acceleration/destabilization of the C3 convertase (C3bBb). Vitronectin, a
soluble regulator, prevents MAC formation by interacting with and blocking membrane
insertion of the terminal C3b5-8 assemblage. Membrane protein CD-59 inhibits MAC
formation by interacting with membrane-associated C3b5-8/-9 and preventing C9
incorporation and polymerization. These mechanisms are employed by the host to
prevent inappropriate and injurious complement activation, but can be exploited by
pathogens during the infectious process.
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for persistence within the host. Whether this mechanism is direct and non-redundant, or
multifactorial and complex, continued analyses of Bh YORΔfhbA and generation of novel RF
spirochete mutants may prove critical to its elucidation.
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